HDAC9 Polymorphism Alters Blood Gene Expression in Patients with Large Vessel Atherosclerotic Stroke
The histone deacetylase 9 (HDAC9) polymorphism rs2107595 is associated with an increased risk for large vessel atherosclerotic stroke (LVAS). In humans, there remains a need to better understand this HDAC9 polymorphism’s contribution to large vessel stroke. In this pilot study, we evaluated whether the HDAC9 polymorphism rs2107595 is associated with differences in leukocyte gene expression in patients with LVAS. HDAC9 SNP rs2107595 was genotyped in 155 patients (43 LVAS and 112 vascular risk factor controls). RNA isolated from blood was processed on whole genome microarrays. Gene expression was compared between HDAC9 risk allele-positive and risk allele-negative LVAS patients and controls. Functional analysis identified canonical pathways and molecular functions associated with rs2107595 in LVAS. In HDAC9 SNP rs2107595 risk allele-positive LVAS patients, there were 155 genes differentially expressed compared to risk allele-negative patients (fold change > |1.2|, p < 0.05). The 155 genes separated the risk allele-positive and risk allele-negative LVAS patients on a principal component analysis. Pathways associated with HDAC9 risk allele-positive status involved IL-6 signaling, cholesterol efflux, and platelet aggregation. These preliminary data suggest an association with the HDAC9 rs2107595 risk allele and peripheral immune, lipid, and clotting systems in LVAS. Further study is required to evaluate whether these differences are related to large vessel atherosclerosis and stroke risk.
KeywordsSNP Polymorphism Gene expression Large vessel stroke Ischemic stroke Atherosclerosis
This study was completed with funds from the American Heart Association (GCJ) and the National Institutes of Health (FRS, BS, GCJ: NS075035, NS079153, NS097000).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients or their surrogates provided informed consent for this study.
- 5.Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng YC, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol. 2012;11:951–62. https://doi.org/10.1016/S1474-4422(12)70234-X. CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Wang XB, Han YD, Sabina S, et al. HDAC9 variant Rs2107595 modifies susceptibility to coronary artery disease and the severity of coronary atherosclerosis in a Chinese Han population. PloS one. 2016;11:e0160449. 2016/08/06. https://doi.org/10.1371/journal.pone.0160449.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Cao Q, Rong S, Repa JJ, Clair RS, Parks JS, Mishra N. Histone deacetylase 9 represses cholesterol efflux and alternatively activated macrophages in atherosclerosis development. Arterioscler, Thromb, Vasc Biol. 2014;34:1871–9. 2014/07/19. https://doi.org/10.1161/atvbaha.114.303393.CrossRefGoogle Scholar
- 14.Bai Z, Stamova B, Xu H, Ander BP, Wang J, Jickling GC, et al. Distinctive RNA expression profiles in blood associated with Alzheimer’s disease after accounting for white matter hyperintensities. Alzheimer Dis Assoc Disord. 2014;28:226–33. https://doi.org/10.1097/WAD.0000000000000022.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Ikeda K, Kundu RK, Ikeda S, et al. Glia maturation factor-gamma is preferentially expressed in microvascular endothelial and inflammatory cells and modulates actin cytoskeleton reorganization. Circ Res. 2006;99:424–33. 2006/07/29. https://doi.org/10.1161/01.RES.0000237662.23539.0b.CrossRefPubMedGoogle Scholar
- 32.Meurs I, Calpe-Berdiel L, Habets KL, et al. Effects of deletion of macrophage ABCA7 on lipid metabolism and the development of atherosclerosis in the presence and absence of ABCA1. PloS one. 2012;7:e30984. 2012/03/10. https://doi.org/10.1371/journal.pone.0030984.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Tuteja S, Wang L, Dunbar RL, Chen J, DerOhannessian S, Marcovina SM, et al. Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy. Pharmacogenet Genomics. 2017 2017/06/20.;27:285–93. https://doi.org/10.1097/fpc.0000000000000289.CrossRefPubMedGoogle Scholar
- 40.Tsai HJ, Tseng CP. The adaptor protein Disabled-2: new insights into platelet biology and integrin signaling. Thromb J. 2016; 14: 28. 2016/10/22; https://doi.org/10.1186/s12959-016-0101-5.
- 44.Della-Morte D, Beecham A, Dong C, et al. Association between variations in coagulation system genes and carotid plaque. J Neurol Sci 2012; 323: 93-98. 2012/09/18. DOI: https://doi.org/10.1016/j.jns.2012.08.020.